This institute is developing proprietary Toll-like receptor (TLR) ligand-based adjuvant systems and vaccines for infectious diseases and cancer. Their adjuvants consist of a TLR 2 ligand and a TLR 3 ligand which synergistically enhance humoral and cellular immunity.
CHA Vaccine Institute
Category:
Large
Main Business Area
Toll-like receptor (TLR) ligand-based adjuvant systems and vaccines
| Contact Details | 560 Dunchon-daero, Jungwon-gu, Seongnam-si, Gyeonggi-do, Korea 13230Tel. 82-31-737-8208 |
|---|
